Woburn, MA, United States of America

Rosa E Mele'ndez

USPTO Granted Patents = 1 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Rosa E Mele'ndez: Pioneering Research in CNS Disorders

Introduction

Rosa E Mele'ndez, based in Woburn, MA, has made significant contributions to the field of pharmacology with her innovative research on compounds targeting 5-HT receptors. Her efforts are particularly focused on therapeutic agents that address various central nervous system disorders, making her a notable figure in the medical research community.

Latest Patents

Rosa holds a patent for piperidinylamino-thieno[2,3-d] pyrimidine compounds, recognized under the category of 5-HT receptor antagonists. This invention encompasses novel compounds detailed by Formula I, highlighting their synthesis and applications in treating a range of conditions mediated by 5-HT receptors. These conditions include anxiety, depression, schizophrenia, neural injury, stroke, and migraine. The patent also outlines methods of preparation and novel intermediates, as well as the pharmaceutical salts associated with these compounds.

Career Highlights

Currently, Rosa E Mele'ndez is affiliated with Predix Pharmaceuticals Holdings, Inc., where her research and development efforts are geared toward creating effective treatments for mental health disorders. Her expertise in pharmacology has positioned her as a key contributor in her field, paving the way for advancements that can potentially enhance the quality of life for many patients.

Collaborations

Throughout her career, Rosa has worked alongside esteemed colleagues, including Dale S Dhanoa and Oren Becker. These collaborations have fostered an environment of innovation and knowledge sharing, essential for the development of new and effective therapeutic solutions.

Conclusion

In summary, Rosa E Mele'ndez stands out as an influential inventor and researcher in the pharmaceutical industry. Her patented work on piperidinylamino-thieno[2,3-d] pyrimidine compounds exemplifies her commitment to advancing medical science, particularly in the treatment of central nervous system disorders. As she continues her work at Predix Pharmaceuticals Holdings, Inc., the impact of her innovations is sure to resonate within the healthcare community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…